A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder

NCT04338321 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

676

Enrollment

INDUSTRY

Sponsor class

Conditions

Depressive Disorder, Major

Interventions

DRUG: Esketamine 28 mg
DRUG: Esketamine 56 mg
DRUG: Esketamine 84 mg
DRUG: Quetiapine XR 50 mg
DRUG: Quetiapine XR 100 mg
DRUG: Quetiapine XR 150 mg
DRUG: SSRI/SNRI

Sponsor

Janssen-Cilag International NV